UNSPSC 51101685: Sulazuril

This classification denotes an antiprotozoal agent and antihelminthic with the molecular formula C17H15Cl2N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2136B7T7KE, chemically known as 2-(3,5-dichloro-4-(p-(methylsulfonyl)phenoxy)phenyl)dihydro-1-methyl-as-triazine-3,5(2h,4h)-dione but generally known as sulazuril, which bears US NIH Compound Identifier 65904. European Medicines Agency schedules Sulazuril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10675MIG.

UNSPSC 51101685 Sulazuril is a Commodity code that, based on recent state and local opportunities, covers pharmaceutical and medical supply procurement rather than the sulazuril antiprotozoal agent the code name suggests. State and local governments are actively sourcing generic pharmaceuticals, over-the-counter products, emergency medical supplies, and naloxone through this code family. The issuing bodies span state health agencies, counties, cities, and cooperative purchasing alliances — including the Texas Health and Human Services Commission, Seminole County Florida, the City of Tampa, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering purchases on behalf of participating state and local members in Minnesota and Oregon.

Recent activity shows geographic spread across Florida, Texas, Minnesota, and Oregon, with solicitations ranging from narrow local buys to multi-state cooperative arrangements. The City of Tampa issued IFB 26P00145 on March 25, 2026, seeking 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with a $700,000 estimated value and a 5 percent SLBE bid discount, response due March 13, 2026. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, response due July 26, 2023. The Minnesota Department of Administration issued MMCAP RFP S1070000015802 on January 20, 2026, seeking generic multi-source pharmaceuticals and OTC products from manufacturers to supply through three authorized wholesalers, with proposals due March 26, 2026 and contract awards effective July 1, 2026. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program as preliminary market research before formal procurement.